DK2421879T3 - Nye 7-deazapurinnukleotider til terapeutiske anvendelser - Google Patents

Nye 7-deazapurinnukleotider til terapeutiske anvendelser

Info

Publication number
DK2421879T3
DK2421879T3 DK10734433.5T DK10734433T DK2421879T3 DK 2421879 T3 DK2421879 T3 DK 2421879T3 DK 10734433 T DK10734433 T DK 10734433T DK 2421879 T3 DK2421879 T3 DK 2421879T3
Authority
DK
Denmark
Prior art keywords
new
therapeutic applications
deazapurine nucleotides
deazapurine
nucleotides
Prior art date
Application number
DK10734433.5T
Other languages
English (en)
Inventor
Aurelie Bourderioux
Michal Hocek
Petr Naus
Original Assignee
Acad Of Science Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acad Of Science Czech Republic filed Critical Acad Of Science Czech Republic
Application granted granted Critical
Publication of DK2421879T3 publication Critical patent/DK2421879T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK10734433.5T 2009-04-22 2010-04-19 Nye 7-deazapurinnukleotider til terapeutiske anvendelser DK2421879T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17165609P 2009-04-22 2009-04-22
PCT/CZ2010/000050 WO2010121576A2 (en) 2009-04-22 2010-04-19 Novel 7-deazapurine nucleosides for therapeutic uses

Publications (1)

Publication Number Publication Date
DK2421879T3 true DK2421879T3 (da) 2013-11-25

Family

ID=42768153

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10734433.5T DK2421879T3 (da) 2009-04-22 2010-04-19 Nye 7-deazapurinnukleotider til terapeutiske anvendelser

Country Status (16)

Country Link
US (3) US9321800B2 (da)
EP (1) EP2421879B1 (da)
JP (2) JP5721275B2 (da)
CN (2) CN102459300B (da)
AU (3) AU2010238985B2 (da)
CA (2) CA2966647A1 (da)
DK (1) DK2421879T3 (da)
ES (1) ES2437917T3 (da)
HK (2) HK1166325A1 (da)
HR (1) HRP20131021T1 (da)
MX (1) MX2011011160A (da)
NZ (2) NZ700583A (da)
PL (1) PL2421879T3 (da)
PT (1) PT2421879E (da)
SI (1) SI2421879T1 (da)
WO (1) WO2010121576A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ700583A (en) * 2009-04-22 2016-04-29 Acad Of Science Czech Republic Novel 7-deazapurine nucleosides for therapeutic uses
AU2010330823A1 (en) * 2009-12-18 2012-07-05 Joslin Diabetes Center, Inc. Beta-cell replication promoting compounds and methods of their use
CN102319254B (zh) * 2011-07-20 2013-06-19 上海交通大学 5-碘代杀菌核素在制备抗肿瘤药物中的应用
CZ305466B6 (cs) * 2013-11-04 2015-10-14 Ústav organické chemie a biochemie Akademie věd České republiky, v. v. i. Substituované 7-deazapurinové ribonukleosidy pro terapeutické použití
MX2017006366A (es) 2014-11-14 2018-02-01 Nerviano Medical Sciences Srl Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
JP6650074B2 (ja) 2016-06-29 2020-02-19 ウスタフ オルガニッケ ヘミエ アー ビオヘミエ アカデミエ ヴェド ツェーエル,ヴェー.ヴェー.イー 治療に使用するための、置換チエノピロロピリミジンリボヌクレオシド
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
WO2019076633A1 (en) 2017-10-19 2019-04-25 Universiteit Gent NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS
CN111971286B (zh) * 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
TW201938169A (zh) * 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
JP7446282B2 (ja) * 2018-08-07 2024-03-08 メルク・シャープ・アンド・ドーム・エルエルシー Prmt5阻害剤
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
EP3988174A4 (en) * 2019-06-18 2023-04-26 Taiho Pharmaceutical Co., Ltd. NEW CARBONATE COMPOUND HAVING A PYROLO-PYRIMIDINE SKELETON OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
US20230104311A1 (en) * 2020-02-17 2023-04-06 Katholieke Universiteit Leuven Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
WO2022180784A1 (ja) 2021-02-26 2022-09-01 株式会社日立インダストリアルプロダクツ 回転電機
CA3233416A1 (en) 2021-09-28 2023-04-06 Universiteit Antwerpen Nucleoside analogues for the treatment of parasitic infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
EP1539188B1 (en) * 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
NZ536123A (en) * 2002-05-06 2006-09-29 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
US20040157892A1 (en) 2003-02-12 2004-08-12 Crompton Co./Cie Pesticidal fluoroethyl pyrazoles
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7169918B2 (en) 2003-10-27 2007-01-30 Genelabs Technologies, Inc. Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
MXPA06004680A (es) * 2003-10-27 2007-04-17 Genelabs Tech Inc Compuestos de nucleosido para el tratamiento de infecciones virales.
JP2008508319A (ja) * 2004-07-29 2008-03-21 メタバシス・セラピューティクス・インコーポレイテッド 新規ヌクレオシド誘導体
PT3133080T (pt) * 2008-01-18 2018-11-16 Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleósidos de 7-deazapurina citostáticos inovadores
KR20110019438A (ko) * 2008-06-23 2011-02-25 얀센 파마슈티카 엔.브이. Ccr2의 피페리딜 아크릴아미드 길항제
GB0815968D0 (en) * 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
NZ700583A (en) * 2009-04-22 2016-04-29 Acad Of Science Czech Republic Novel 7-deazapurine nucleosides for therapeutic uses

Also Published As

Publication number Publication date
AU2017204148B2 (en) 2018-12-06
CN104497084A (zh) 2015-04-08
EP2421879A2 (en) 2012-02-29
CN102459300A (zh) 2012-05-16
US20160318970A1 (en) 2016-11-03
NZ700583A (en) 2016-04-29
CN104497084B (zh) 2018-06-05
EP2421879B1 (en) 2013-09-04
US10294262B2 (en) 2019-05-21
US20150218201A1 (en) 2015-08-06
US20170240584A1 (en) 2017-08-24
WO2010121576A3 (en) 2011-06-16
JP2015013901A (ja) 2015-01-22
CA2759131A1 (en) 2010-10-28
NZ596301A (en) 2014-10-31
AU2015205885B2 (en) 2017-04-06
CA2966647A1 (en) 2010-10-28
MX2011011160A (es) 2012-01-27
US9624257B2 (en) 2017-04-18
HK1209129A1 (en) 2016-03-24
AU2015205885A1 (en) 2015-09-03
JP6087889B2 (ja) 2017-03-01
PT2421879E (pt) 2013-12-09
ES2437917T3 (es) 2014-01-15
AU2017204148A1 (en) 2017-07-06
HK1166325A1 (en) 2012-12-14
JP5721275B2 (ja) 2015-05-20
HRP20131021T1 (hr) 2014-01-31
CN102459300B (zh) 2014-12-10
JP2012524731A (ja) 2012-10-18
AU2010238985B2 (en) 2015-04-23
CA2759131C (en) 2017-06-20
PL2421879T3 (pl) 2014-02-28
US9321800B2 (en) 2016-04-26
WO2010121576A2 (en) 2010-10-28
AU2010238985A1 (en) 2011-12-01
SI2421879T1 (sl) 2014-01-31

Similar Documents

Publication Publication Date Title
DK2421879T3 (da) Nye 7-deazapurinnukleotider til terapeutiske anvendelser
CY2020008I1 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
SMT201700008B (it) Composizione farmaceutica
SMT201700095B (is) Composizioni farmaceutiche per inalazione
DK3097925T3 (da) Farmaceutisk sammensætning
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
BRPI1004940A2 (pt) composição farmacêutica
ATE557381T1 (de) Präsentationssäule
DK3246018T3 (da) Farmaceutisk sammensætning
SMT201400069B (it) Formulazione farmaceutica
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
BRPI1015939A2 (pt) composição farmacêutica
DK2399606T3 (da) Fremgangsmåde til fremstilling af varmebestandig oxygenbærerholdig farmaceutisk sammensætning
EE201300005A (et) Ravimkoostis
BRPI1014688A2 (pt) aplicações terapêuticas de derivados de quinazolinadiona
DK2649029T3 (da) Fremgangsmåde til depolymerisering
UY33111A (es) Jeringas
BR112013015097A2 (pt) coluna de perfuração
BR112012003149A2 (pt) composição farmacêutica
FR2959228B1 (fr) Nucleotides modifies
FI20106109A0 (fi) Pilarikenkä
FI20106110A (fi) Pilarikenkä
ITPD20090053U1 (it) Paradordi per banchine
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
DK2394638T3 (da) Nye farmaceutiske sammensætninger